← Back to Clinical Trials
Recruiting NCT07388004

NCT07388004 Group Therapy for Major Depression: Comparing Expectation-Focused and Reward-Focused Psychotherapy Approaches

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07388004
Status Recruiting
Phase
Sponsor Philipps University Marburg
Condition Major Depressive Disorder (MDD)
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2025-10-13
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Expectation-Focused Psychotherapeutic InterventionReward Enhancement and Activation Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2025-10-13 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Major depressive disorder (MDD) is one of the most common psychiatric conditions and often remains difficult to treat effectively. Many patients continue to experience residual symptoms or relapse even after receiving established forms of psychotherapy. This study tests whether targeting specific psychological mechanisms can improve outcomes for people with depression. We compare two novel group therapies: (1) Expectation-Focused Psychotherapeutic Intervention (EFPI), which aims to modify rigid, negative expectations that maintain depressive symptoms, and (2) Reward Enhancement and Activation Therapy (REACT), which focuses on increasing sensitivity to positive experiences and strengthening reward-related learning. Both are delivered in a group format to foster peer support and shared learning. A total of 150 adults with a current MDD diagnosis will be randomly assigned to EFPI, REACT, or a waiting-list control. Participants in the intervention groups receive 10 group sessions over five weeks. Waiting-list participants complete baseline and 3-month follow-up assessments before being offered standard treatment options. Clinical outcomes are assessed at baseline, immediately after treatment, and at 3- and 6-month follow-ups (for the intervention groups). Primary outcomes are reductions in depressive symptoms measured by clinician ratings and self-report questionnaires. Secondary outcomes include changes in expectation processes and reward sensitivity. In addition, functional MRI (fMRI) tasks examine brain mechanisms related to expectation updating and reward processing pre- and post-intervention, to help identify neural changes that may underlie symptom improvement. By directly addressing dysfunctional expectations and reduced reward sensitivity, this study seeks to provide evidence for more targeted psychotherapeutic approaches. If successful, the results may support more personalized treatments and better long-term outcomes in MDD.

Eligibility Criteria

Inclusion Criteria: * Age: 18-80 years * Current diagnosis of major depressive disorder (MDD) according to DSM-5, confirmed by structured clinical interview (e.g., DIPS) * Hamilton Depression Rating Scale (HAMD-21) score ≥ 9 * Ability to attend group therapy sessions (2×/week for 5 weeks) * Ability to undergo MRI scanning (for participants in the fMRI component) Written informed consent Exclusion Criteria: * Current or lifetime diagnosis of bipolar disorder, psychotic disorder, or primary substance use disorder * High acute suicide risk requiring immediate intervention * Severe neurological disorder, brain injury, or contraindications for MRI (e.g., metal implants, claustrophobia) * Ongoing psychotherapy or initiation of a new antidepressant medication within the past 4 weeks * Insufficient German language proficiency to participate in therapy and complete study assessments * Cognitive impairment or other conditions interfering with informed consent or study participation

Contact & Investigator

Central Contact

Masia Fernanda Hoffmann, M.Sc.

✉ fernanda.hoffmann@uni-marburg.de

📞 +4917656538480

Principal Investigator

Winfried Rief, Prof. Dr.

PRINCIPAL INVESTIGATOR

Philipps University Marburg

Frequently Asked Questions

Who can join the NCT07388004 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Major Depressive Disorder (MDD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07388004 currently recruiting?

Yes, NCT07388004 is actively recruiting participants. Contact the research team at fernanda.hoffmann@uni-marburg.de for enrollment information.

Where is the NCT07388004 trial being conducted?

This trial is being conducted at Marburg, Germany.

Who is sponsoring the NCT07388004 clinical trial?

NCT07388004 is sponsored by Philipps University Marburg. The principal investigator is Winfried Rief, Prof. Dr. at Philipps University Marburg. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology